Dapitant is a non-peptide substance P antagonist with high affinity for the human NK1 receptor. It inhibits the binding of substance P to the NK1 receptor, thereby blocking its neurokinin-mediated effects. This novel antagonist represents a potential therapeutic option for substance P-related disorders, such as neurogenic inflammation and pain modulation.